The Irish Atopic Eczema Systemic Therapy Register (ASTAR)
ASTAR is an observational study that aims to collect data on children (no lower age cut off) and adults with atopic eczema, Starting on or switching to another systemic immuno-modulatory therapy (e.g. ciclosporin, azathioprine, methotrexate or biologic treatments). The study aims to monitor patients for at least 12 months but if possible for 10 years. The study is observational and does not involve a study specific intervention. Patient contact will be involved to take explicit consent for participation.
During the observation period, participants will be assessed on a regular (3-6 monthly basis) to collect data on disease severity and other clinical outcomes (such as quality of life), adverse events, reasons for potential changes in therapy and key healthcare resource use (e.g. hospitalisations, specialist and GP visits, and drug use). The latter will form part of the health economic feasibility assessment, which will also examine the potential use of HES and CPRD data for health economic evaluation purposes. The study outcomes are based on the results of a recent international consensus exercise – TREatment of severe Atopic eczema Taskforce (TREAT).
The first study visit occurs at enrolment (baseline visit, V1). V2 and V3 will be scheduled for 4 weeks and 16 weeks and three-monthly thereafter while on systemic therapy. After systemic treatment cessation, patients will be seen at 6-monthly intervals.
**Purpose:** The Irish Atopic Eczema Systemic Therapy Register (ASTAR) is a multicentre, prospective, observational clinical registry of paediatric and adult patients on systemic immuno-modulatory therapies. The primary objective is:
to establish the short- and long-term effectiveness of systemic immune-modulatory therapies in adults and children.
Secondary objectives include clinical data collection to:
• assess the short- and long-term safety (pharmacovigilance) of atopic eczema therapies, for instance w
**Coverage:** National and the study duration is ongoing.
Health Category
Language
Access Rights
- Organization
- National Skin Registry Solutions
- License
- Creative Commons Attribution
Metadata
| Field | Value |
|---|---|
| Access Rights | http://publications.europa.eu/resource/authority/access-right/PUBLIC |
| Frequency | http://publications.europa.eu/resource/authority/frequency/MONTHLY |
| Id | 5d13302f-9af8-4034-8fbc-63109288266d |
| Identifier | NDC-0122 |
| Isopen | True |
| Issued | 2022-01-01 |
| License Id | cc-by |
| License Title | Creative Commons Attribution |
| License Url | http://www.opendefinition.org/licenses/cc-by |
| Max Typical Age | 85 |
| Metadata Created | 2026-03-19T17:17:18.335033 |
| Metadata Modified | 2026-03-19T17:17:18.335036 |
| Min Typical Age | 15 |
| Modified | 2025-03-01 |
| Name | the-irish-atopic-eczema-systemic-therapy-register-astar-122 |
| Notes | ASTAR is an observational study that aims to collect data on children (no lower age cut off) and adults with atopic eczema, Starting on or switching to another systemic immuno-modulatory therapy (e.g. ciclosporin, azathioprine, methotrexate or biologic treatments). The study aims to monitor patients for at least 12 months but if possible for 10 years. The study is observational and does not involve a study specific intervention. Patient contact will be involved to take explicit consent for participation. During the observation period, participants will be assessed on a regular (3-6 monthly basis) to collect data on disease severity and other clinical outcomes (such as quality of life), adverse events, reasons for potential changes in therapy and key healthcare resource use (e.g. hospitalisations, specialist and GP visits, and drug use). The latter will form part of the health economic feasibility assessment, which will also examine the potential use of HES and CPRD data for health economic evaluation purposes. The study outcomes are based on the results of a recent international consensus exercise – TREatment of severe Atopic eczema Taskforce (TREAT). The first study visit occurs at enrolment (baseline visit, V1). V2 and V3 will be scheduled for 4 weeks and 16 weeks and three-monthly thereafter while on systemic therapy. After systemic treatment cessation, patients will be seen at 6-monthly intervals. **Purpose:** The Irish Atopic Eczema Systemic Therapy Register (ASTAR) is a multicentre, prospective, observational clinical registry of paediatric and adult patients on systemic immuno-modulatory therapies. The primary objective is: to establish the short- and long-term effectiveness of systemic immune-modulatory therapies in adults and children. Secondary objectives include clinical data collection to: • assess the short- and long-term safety (pharmacovigilance) of atopic eczema therapies, for instance w **Coverage:** National and the study duration is ongoing. |
| Num Resources | 0 |
| Num Tags | 4 |
| Number Of Records | 1703976 |
| Number Of Unique Individuals | 462407 |
| Private | False |
| Provenance | Enrolment in the registry is subject to a process of gaining informed explicit consent from patients or their parents or carer (if under 18). Participation is voluntary. The data is then collected from the patients charts after their standard clinic visits and entered onto the registry platform. Data is collected from patient medical charts and input into a secure internet-based computer database. Data collection is undertaken by EB registry data collectors. Data is collected on a continual basis throughout the year and EB data collectors collect data on an encounter basis. |
| Title | The Irish Atopic Eczema Systemic Therapy Register (ASTAR) |
| Type | dataset |
No history available for this dataset.